5-AMINO-1 MQ

Beschrijving

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and depletes NAD+ pools while contributing to fat storage and metabolic slowdown. By blocking NNMT activity, 5-Amino-1MQ preserves intracellular NAD+ levels, enhances mitochondrial function, activates sirtuins (especially SIRT1, the “longevity protein”), increases energy expenditure, promotes lipolysis (fat breakdown), inhibits lipogenesis (new fat formation), and supports improved insulin sensitivity without suppressing appetite or causing major toxicity in preclinical models. Animal studies in diet-induced obese mice show significant reductions in body weight, white adipose tissue mass, adipocyte size, plasma cholesterol, and total fat content—often with preserved lean mass and negligible side effects at tested doses. Additional research indicates potential benefits for muscle regeneration (reversing age-related decline in muscle progenitor cells), enhanced grip strength and endurance in aged models, and metabolic improvements in obesity-linked conditions. In wellness, biohacking, and metabolic health communities, 5-Amino-1MQ is explored orally (capsules typically 50mg 1–3 times daily) or via subcutaneous injection for gradual fat reduction, muscle preservation during calorie deficits, increased vitality, better recovery, and synergy with NAD+ therapies or other longevity compounds. Users report improvements in energy, body composition, and metabolic markers over weeks to months when paired with proper nutrition and training. While preclinical data is promising and mechanistic pathways are well-supported, 5-Amino-1MQ is not FDA-approved for any therapeutic, weight loss, anti-aging, metabolic, or medical use as of 2026—no large-scale human clinical trials have been completed to confirm long-term efficacy, safety, optimal dosing, or tolerability in people. Evidence relies on animal models, cell studies, and widespread anecdotal/user reports rather than rigorous randomized controlled human data. Reported side effects are generally mild (occasional gastrointestinal upset, headache, appetite changes, or fatigue), but unknowns remain regarding long-term metabolic impacts, potential off-target effects, or interactions with medications affecting NAD+ pathways. It is prohibited by WADA for athletes and should never be used without supervision from a qualified healthcare provider experienced in metabolic or peptide therapies, with monitoring of labs (glucose, lipids, liver function) and proper sourcing from reputable suppliers. Always combine with evidence-based lifestyle interventions—balanced diet, exercise, sleep—for metabolic or body composition goals. Consult a professional to assess suitability and stay informed on emerging research or regulatory developments. 5-Amino-1MQ is not a substitute for proven medical treatments or approved therapies.